No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes
Autor: | Johan Löfgren, Maria S. Svane, Christoffer Martinussen, Andreas Kjaer, Bolette Hartmann, Helle Hjorth Johannesen, Nicolai J. Wewer Albrechtsen, Thomas Levin Klausen, Adam E. Hansen, Sune H. Keller, Jens J. Holst, Martin Hansen, Annika Loft, Carolyn F. Deacon, Sten Madsbad, Kirstine N. Bojsen-Møller |
---|---|
Rok vydání: | 2020 |
Předmět: |
Agonist
Adult Male medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Glucagon-Like Peptide-1 Receptor 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Clinical endpoint Edema Humans Hypoglycemic Agents Obesity Receptor Glucagon-like peptide 1 receptor business.industry Liraglutide Middle Aged medicine.disease Cellular infiltration Diabetes Mellitus Type 2 business Body mass index medicine.drug |
Zdroj: | Diabetes, obesitymetabolismREFERENCES. 22(10) |
ISSN: | 1463-1326 |
Popis: | AIM To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans. MATERIALS AND METHODS We performed an open-label study in 14 obese men (age 38 ± 11 years, body mass index 32 ± 4 kg/m2 ) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [18 F]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes. RESULTS Plasma amylase (+7 U/L [95% confidence intervals 3-11], P |
Databáze: | OpenAIRE |
Externí odkaz: |